Company Profile

bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths, with the potential to dramatically increase overall diagnostic accuracy of lung cancer leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.

Industry Classifications

Sector:
Biotechnology

Industry:
In vitro Diagnostics

NAICS:
Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC:
Commercial Physical and Biological Research (8731)

Contact Information

Investor Relations
Tiberend Strategic Advisors, Inc.
35 W. 35th Street
11th Floor
New York, NY 10001-0080
T: 212-375-2689

Jonathan Nugent
jnugent@tiberend.com

David Irish
dirish@tiberend.com

Company Contact
bioAffinity Technologies, Inc.
22211 West Interstate 10
Suite 1204
San Antonio, TX 78257
T: 210-698-5334
info@bioaffinitytech.com